Graham Powers, MD
Family Medicine · South Hill, VANPI 1518965177
Payments from drug & device makers
Across 180 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$703
- Novo Nordisk$543
- Pfizer$297
- Amgen$219
- Lilly USA, LLC$104
- Novartis$88
- plus $669 from 24 others
What the payments were for
- Food & beverage$2,59499%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $703 |
| Novo Nordisk | 40 | $543 |
| Pfizer | 20 | $297 |
| Amgen | 16 | $219 |
| Lilly USA, LLC | 8 | $104 |
| Novartis | 5 | $88 |
| Amarin Pharma, Inc. | 4 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Bayer | 4 | $50 |
| GSK | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| AstraZeneca | 3 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Phadia US Inc. | 2 | $29 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Boehringer Ingelheim | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Abbott | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Preventice Services, LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
How this compares
$2,622 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 326 | $304,619 |
| JardianceEmpagliflozin | 160 | $201,042 |
| MounjaroTirzepatide | 122 | $133,423 |
| XareltoRivaroxaban | 53 | $69,829 |
| FarxigaDapagliflozin Propanediol | 45 | $64,605 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $56,926 |
| RybelsusSemaglutide | 37 | $56,771 |
| OzempicSemaglutide | 45 | $51,798 |
| EntrestoSacubitril/Valsartan | 58 | $47,762 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $41,537 |
| JanuviaSitagliptin Phosphate | 34 | $29,573 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 151 | $27,297 |
| Repatha SureclickEvolocumab | 25 | $26,872 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $23,049 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 72 | $22,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $297 | $304,619326 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat | $25 | $244,445210 claims |
| Lilly USA, LLCMounjaro | $104 | $133,423122 claims |
| Novo NordiskRybelsus, Ozempic | $543 | $108,57082 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $35 | $92,31099 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $40 | $71,037153 claims |
| MerckJanuvia, Janumet Xr, Janumet | $12 | $66,03575 claims |
| NovartisEntresto | $88 | $47,76258 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $36 | $28,52357 claims |
| AbbVieLinzess | $703 | $15,75418 claims |
| Astellas Pharma US IncMyrbetriq | $11 | $11,50216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in South Hill
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.